Momentum in MDS: Making Progress and Shaping a Better Future (IN-PERSON EVENT)

In recent years, significant progress has been made in understanding the biology, genetics, and pathogenesis of myelodysplastic syndromes (MDS). These advances have led to meaningful developments in how the disease is diagnosed, risk-stratified, and managed—insights that will be reflected in the upcoming revision of the international treatment guidelines, set to be presented and published by a leading global consortium of MDS experts.

Among the evolving topics in the field is the role of morphology in modern medicine—a question that has become increasingly relevant in 2025. This issue will be explored in depth during the program, along with an important discussion on the implications of germline mutations in MDS patients and how this growing body of knowledge necessitates a reassessment of current clinical approaches.

The continued need for more effective therapies has also inspired the inclusion of a dedicated session on drug development, with a specific focus on the MDS pipeline.

Aligned with our patient-centeredness, the program will also feature a patient-centered discussion to bridge the gap between scientific advancements and the lived experience of those navigating MDS in real-world settings.